Todd Crocenzi
Providence Health & Services
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Todd Crocenzi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02688712 · ExIST Study of LY2157299 (Galunisertib) in Rectal CancerProvidence Health & Services · active not recruiting · Rectal Adenocarcinoma · principal investigator
- Ph1NCT01903083 · Chemoimmunotherapy and Radiation in Pancreatic CancerProvidence Health & Services · completed · Locally Advanced Malignant Neoplasm · principal investigator
- Ph1NCT01342224 · Immunochemoradiotherapy in Patients With Pancreatic CancerProvidence Health & Services · completed · Locally Advanced Pancreatic Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:02 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med · 20157,784 citationsRCR 243.1
- 5,520 citationsRCR 184.9
- 3,555 citationsRCR 120.7
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.J Clin Oncol · 2020810 citationsRCR 32.3
- Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.J Clin Oncol · 2015503 citationsRCR 14.1
- 397 citationsRCR 9.7
- Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.Clin Cancer Res · 2020141 citationsRCR 5.3
- 111 citationsRCR 4.3
- 103 citationsRCR 2.6
- Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.Clin Cancer Res · 200984 citationsRCR 1.7